Proqr Therapeutics (PRQR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,664 | -47,727 | -38,882 | -25,267 | -10,618 |
| Depreciation Amortization | 812 | 3,058 | 2,366 | 1,536 | 714 |
| Other Working Capital | 128 | -19,706 | -12,828 | -8,968 | -7,081 |
| Other Operating Activity | 1,680 | 4,647 | 3,250 | 1,823 | 341 |
| Operating Cash Flow | $-13,044 | $-59,728 | $-46,094 | $-30,876 | $-16,643 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -192 | -1,154 | -577 | -369 | -236 |
| Investing Cash Flow | $-192 | $-1,154 | $-577 | $-369 | $-236 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 78 | 78 | 76 | 71 |
| Other Financing Activity | -356 | -2,155 | -1,524 | -976 | -597 |
| Financing Cash Flow | $-356 | $-2,077 | $-1,446 | $-900 | $-527 |
| Exchange Rate Effect | 337 | -1,525 | -1,590 | -1,505 | -497 |
| Beginning Cash Position | 108,160 | 169,040 | 174,643 | 169,608 | 157,401 |
| End Cash Position | 94,905 | 104,556 | 124,936 | 135,957 | 139,498 |
| Net Cash Flow | $-13,255 | $-64,484 | $-49,708 | $-33,651 | $-17,903 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,044 | -59,728 | -46,094 | -30,876 | -16,643 |
| Capital Expenditure | -192 | -1,154 | -577 | -369 | -236 |
| Free Cash Flow | -13,236 | -60,882 | -46,672 | -31,245 | -16,879 |